PubMed Health⌕ Search

Biomedical subjects

D A Baker

Publications and source records attributed to D A Baker.

At least 19 recordsLinked to original sources
PubMed1999

Study of fatigue resistance of chemical and radiation crosslinked medical grade ultrahigh molecular weight polyethylene.

The aim of this work is to understand the role of chemical and radiation induced crosslinking on the fatigue crack propagation resistance of medical grade ultrahigh molecular weight polyethylene (UHMWPE). In recent years, the need to improve the tribological performance of UHMWPE used in total joint replacements has resulted in the widespread utilization of crosslinking as a method to improve wear resistance. Although crosslinking has been shown to drastically improve the wear resistance of the polymer, the potential trade-off in fatigue properties has yet to be addressed. Fatigue crack propagation resistance is a concern in tibial inserts where large cyclic stresses are sufficient to drive the growth of subsurface cracks that potentially contribute to delamination wear mechanisms. For clinical relevance, the combined effects of sterilization and aging are examined in two commercially available crosslinked resins. Nonsterile and unaged resins serve as a control. To evaluate the effect of crosslinking, a comparison is made to uncrosslinked resins. Scanning electron microscopy is used to provide an understanding of fatigue fracture mechanisms in the crosslinked polymers. The results of this study show that the current level of crosslinking used in orthopedic resins for enhanced wear resistance is not beneficial for fatigue crack propagation resistance.

Biocompatible Materials↗
PubMed1999

Once-daily valacyclovir hydrochloride for suppression of recurrent genital herpes.

OBJECTIVE: To document the frequency of genital herpes recurrences in men and women with histories of recurrent genital herpes during 1 year of continuous, suppressive therapy with valacyclovir hydrochloride (HCl). METHODS: In an open-label clinical trial conducted at 11 centers, 127 subjects (46 women and 81 men) with histories of recurrent genital herpes (at least 6 recurrences per year) were treated with valacyclovir HCl (500 mg once daily), and their clinical status was followed up for 1 year. Genital herpes recurrences were documented in diaries, and quarterly clinic visits were made for evaluating lesion recurrences and drug safety. In cases of recurrence, subjects self-treated with valacyclovir HCl 500 mg twice daily for 5 days, then resumed once-daily treatment. RESULTS: After the first 3 months of suppressive therapy, 81% of subjects were free of recurrence. Recurrence-free rates remained undiminished during the second, third, and fourth quarters (84%, 84%, and 91%, respectively) and were similar for men and women. Thirty of 46 women (65%) and 56 of 81 men (69%) remained recurrence free during the study and therapy was well tolerated. Adverse events were mild, infrequent, and not considered related to the study drug. CONCLUSION: Valacyclovir HCl was highly effective and well tolerated as continuous suppressive therapy in men and women with recurrent genital herpes. Potential benefits of the once-daily regimen of valacyclovir HCl include improved patient compliance.

Acyclovir↗
PubMed1998

Effects of intraaccumbens administration of SCH-23390 on cocaine-induced locomotion and conditioned place preference.

The effects of systemic (0-1.0 mg/kg) or intraaccumbens (0-1.0 microg/side) administration of SCH-23390 on cocaine-induced (0 or 4.2 mg/kg, i.v.) locomotion, sniffing, and conditioned place preference (CPP) were investigated in rats. After behavioral testing was completed, animals were injected with their respective dose of SCH-23390 into the nucleus accumbens (NAc), followed by a systemic injection of the irreversible antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). Receptors occupied by intraaccumbens SCH-23390, and therefore protected from EEDQ-induced inactivation, were then quantified from autoradiograms of sections labeled with 3H-SCH-23390. Systemic administration of 0.5 and 1.0 mg/kg SCH-23390 reversed cocaine-induced locomotion, sniffing, and CPP, suggesting that stimulation of D1-like receptors is necessary for these behavioral changes. Intraaccumbens administration of 1.0 microg/side SCH-23390 reversed cocaine-CPP, and this dose occupied D1-like receptors primarily in the rostral pole of the NAc. Intraaccumbens administration of 0.5 microg/side SCH-23390 reversed cocaine-induced locomotion. However, this dose occupied a similar number of D1-like receptors in the NAc as a lower and behaviorally ineffective dose of 0.1 microg/side, but occupied more receptors in the caudate-putamen relative to both the 0.1 and 1.0 microg/side doses. These findings suggest that stimulation of D1-like receptors in the NAc is necessary for cocaine-CPP, but not for cocaine-induced locomotion.

Animals↗
PubMed1998

Differential effects of 7-OH-DPAT on amphetamine-induced stereotypy and conditioned place preference.

Low doses of the dopamine D3-preferring agonist 7-hydroxy-N,N-di-n-propyl-2-aminotetralin (7-OH-DPAT) produce a behavioral profile that is opposite to that produced by the psychomotor stimulants cocaine and amphetamine. For example, low doses of 7-OH-DPAT produce conditioned place aversion and hypolocomotion, whereas psychomotor stimulants produce conditioned place preference (CPP) and hyperlocomotion. In experiment 1, the effects of low doses of 7-OH-DPAT (0.01-0.1 mg/kg) on d-amphetamine-induced (1 mg/kg) motor behaviors and CPP were assessed. In experiment 2, the effects of 0.1 mg/kg 7-OH-DPAT on d-amphetamine (0-10 mg/kg) dose-response curves for the same behaviors were examined. During conditioning, drug injections were paired with a distinct compartment, whereas saline injections were paired with another compartment. Locomotion and headbobbing were measured following acute and repeated drug administration during conditioning and place conditioning was assessed 24 h following the last conditioning day. In experiment 1, d-amphetamine-induced locomotion was dose-dependently decreased by 7-OH-DPAT following repeated administration, which was probably due to the emergence of headbobbing, a behavior not observed with d-amphetamine alone. d-Amphetamine-CPP was not altered by co-administration of 0-0.03 mg/kg 7-OH-DPAT, but was attenuated by co-administration of 0.1 mg/kg 7-OH-DPAT. In experiment 2, 7-OH-DPAT co-administered with low doses of d-amphetamine (0-0.5 mg/kg) produced a decrease in locomotion following acute administration. However, 7-OH-DPAT produced sensitization of locomotion at the 0.5 mg/kg dose of d-amphetamine and an increase in headbobbing at the 0.5-10 mg/kg doses of d-amphetamine following repeated administration. In contrast, d-amphetamine-CPP was attenuated by co-administration of 7-OH-DPAT. These findings suggest that 0.1 mg/kg 7-OH-DPAT attenuates the reinforcing effects of d-amphetamine despite enhancing stereotypic behaviors.

Amphetamine↗
PubMed1998

Amphetamine infused into the ventrolateral striatum produces oral stereotypies and conditioned place preference.

The effects of amphetamine infused into the ventrolateral striatum (VLS) on locomotion, stereotypies, and conditioned place preference (CPP) were investigated. Five 2-day conditioning trials were conducted over 10 consecutive days. On 1 day of each trial, animals received an infusion of amphetamine (0, 2.5, 5, 10, or 20 mg/0.5 ml/side) and were placed into a distinct compartment for 30 min. On the other day, animals received sham intracranial infusions and were placed into a different compartment for 30 min. Locomotion and stereotypies were assessed following the first and last amphetamine infusions. CPP was assessed the day following the last conditioning trial. Intra-VLS infusions of amphetamine did not alter sniffing or locomotion. Acute administration of amphetamine into the VLS dose dependently produced oral stereotypies, however, tolerance developed to this effect following repeated administrations. Also, intra-VLS infusions of amphetamine dose dependently produced CPP. These results suggest that the VLS is involved in amphetamine-induced oral stereotypies and reward.

Amphetamine↗
PubMed1998

Time-dependent changes in cocaine-seeking behavior and extracellular dopamine levels in the amygdala during cocaine withdrawal.

Cocaine and cocaine-associated cues elicit craving in addicts and reinstate cocaine-seeking behavior in rats. Craving and cocaine-seeking behavior may be mediated by withdrawal-induced changes in dopamine (DA) neurotransmission in the amygdala. To examine whether there are concomittant changes in cocaine-seeking behavior and extracellular DA levels during withdrawal, experimental rats were trained to self-administer cocaine (0.75 mg/kg i.v.). After 14 daily 3-hour training sessions, animals underwent either a 1-day, 1-week, or 1-month withdrawal period. Extracellular DA levels were assessed during baseline, extinction, cue reinstatement, and cocaine (15 mg/kg i.p.) reinstatement of cocaine-seeking behavior (i.e., defined as the difference in nonreinforced lever presses on an active minus inactive lever). Cocaine-seeking behavior became more intense during the course of cocaine withdrawal. Additionally, basal and cocaine-induced extracellular DA levels were enhanced after the 1-month withdrawal period. We suggest that the former may reflect a persistent elevation in tonic extracellular DA levels in the amygdala, whereas the latter may reflect a persistent elevation in phasic extracellular DA levels.

Amygdala↗
PubMed1997

Protein phosphatase beta, a putative type-2A protein phosphatase from the human malaria parasite Plasmodium falciparum.

Protein phosphatases play a critical role in the regulation of the eukaryotic cell cycle and signal transduction. A putative protein serine/threonine phosphatase gene has been isolated from the human malaria parasite Plasmodium falciparum. The gene has an unusual intron that contains four repeats of 32 nucleotides and displays a high degree of size polymorphism among different strains of P. falciparum. The open reading frame reconstituted by removal of the intron encodes a protein of 466 amino acids with a predicted molecular mass of approximately 53.7 kDa. The encoded protein, termed protein phosphatase beta (PP-beta), is composed of two distinct domains. The C-terminal domain comprises 315 amino acids and exhibits a striking similarity to the catalytic subunits of the type-2A protein phosphatases. Database searches revealed that the catalytic domain has the highest similarity to Schizosaccharomyces pombe Ppa1 (58% identity and 73% similarity). However, it contains a hydrophilic insert consisting of five amino acids. The N-terminal domain comprises 151 amino acid residues and exhibits several striking features, including high levels of charged amino acids and asparagine, and multiple consensus phosphorylation sites for a number of protein kinases. An overall structural comparison of PP-beta with other members of the protein phosphatase 2A group revealed that PP-beta is more closely related to Saccharomyces cerevisiae PPH22. Southern blots of genomic DNA digests and chromosomal separations showed that PP-beta is a single-copy gene and is located on chromosome 9. A 2800-nucleotide transcript of this gene is expressed specifically in the sexual erythrocytic stage (gametocytes). The results indicate that PP-beta may be involved in sexual stage development.

Amino Acid Sequence↗
PubMed1997

Advances and prospects in glucose assay technology.

The evolution of glucose assay methods has been central to the development of present therapies for diabetes mellitus. However, new blood glucose assay capabilities, such as convenient and truly continuous monitoring, are now needed to foster a new era of close blood glucose control. The principles and present status of glucose sensors being developed that may fill these requirements are reviewed here.

Animals↗
PubMed1997

Effects of D3-preferring agonists 7-OH-PIPAT and PD-128,907 on motor behaviors and place conditioning.

Dose-dependent effects of 7-OH-PIPAT and PD-128,907 on motor behaviors and place conditioning were examined in rats. Four 2-day conditioning trials were conducted over 8 consecutive days. On one day of each trial, animals received an injection of either saline, one of six doses of 7-OH-PIPAT (0.01-10.0 mg/kg), or one of five doses of PD-128,907 (0.01-1.0 mg/kg), and were placed into a distinct compartment for 40 min. On the other day, animals received an injection of saline and were placed into a different compartment for 40 min. Locomotion, sniffing, and yawning were measured following the first and last drug injections. Place conditioning was assessed the day following the last conditioning trial. None of the doses of 7-OH-PIPAT or 0-0.3 mg/kg PD-128,907 produced place conditioning. However, 1 mg/kg PD-128,907 produced conditioned place preference (CPP). Across doses, both 7-OH-PIPAT and PD-128,907 produced a U-shaped change in sniffing and locomotion and an inverted U-shaped change in yawning. Across time, lower doses produced a decrease in sniffing and locomotion and an increase in yawning that were evident immediately, whereas higher doses produced a biphasic change in that there was an initial decrease followed by an increase in sniffing and locomotion. Behaviors produced by both low and high doses were sensitized following repeated administration. PD-128,907 produced CPP and was more potent than 7-OH-PIPAT in altering motor behaviors, possibly due to its greater selectivity for the D3 receptor.

Animals↗
PubMed1996

Pfmrk, a MO15-related protein kinase from Plasmodium falciparum. Gene cloning, sequence, stage-specific expression and chromosome localization.

Cyclin-dependent kinases (Cdks) play a central role in the regulation of the eukaryotic cell cycle. A novel gene encoding a Cdk-like protein, Pfmrk, has been isolated from the human malaria parasite Plasmodium falciparum. The gene has no introns and comprises an open reading frame encoding a protein of 324 amino acids with a predicted molecular mass of 38 kDa. Database searches revealed a striking similarity to the Cdk subfamily with the highest similarity to human MO15 (Cdk7). The overall sequence of Pfmrk shares 62% similarity and 46% identity with human MO15, in comparison to the 49-58% similarity and 34-43% identity with other human Cdks. Pfmrk contains two unique inserts: one consisting of 5 amino acids just before the cyclin-binding motif and the other composed of 13 amino acids within the T-loop equivalent region. Southern blots of genomic DNA digests and chromosomal separations showed that Pfmrk is a single-copy gene conserved between several parasite strains and is located on chromosome 10. A 2500-nucleotide transcript of this gene is expressed predominantly in the sexual blood stages (gametocytes), suggesting that Pfmrk may be involved in sexual stage development.

Amino Acid Sequence↗
PubMed1996

Dynamic delay and maximal dynamic error in continuous biosensors.

When biosensors are operated continuously, a dynamic delay and a dynamic error relate the sensor signal to the changing analyte concentration. The dynamic delay is the temporal displacement of the signal, or the lag, and is specified solely by properties of the biosensor and external mass transfer. The dynamic error is the difference between the actual concentration and the simultaneous reported concentration and is the product of the dynamic delay and the instantaneous rate of concentration change. In real-time operation of sensors, a maximal dynamic error based on the maximal expected rate of concentration change must be employed to estimate the worst-case error because the actual instantaneous rate is not independently known. Values of dynamic delay and maximal dynamic error that are acceptable in particular monitoring situations can be used in the design of acceptable continuous biosensors. This analysis suggests experimental alternatives to the standard response time approach for sensor characterization that are particularly advantageous for continuously operated biosensors. The concepts are applied here to in vitro operation of a continuous glucose sensor.

Biosensing Techniques↗
PubMed1996

Humoral immune responses in Gambians to Pfs16, an immunodominant, Plasmodium falciparum integral membrane protein.

Naturally acquired humoral immune responses to Pfs16, an integral membrane protein expressed in Plasmodium falciparum gametocytes and sporozoites, were investigated in The Gambia. A high prevalence of antibodies to this molecule was detected by peptide ELISA. Ninety-three per cent of the people taking part in a survey at the end of the rainy season (November) had serum antibodies to one or more synthetic peptides spanning the sequence: 88% reacted with one particular peptide sequence (IMLIILSGIVGFKVK) whereas only one out of ten non-Gambians (taking anti-malarial prophylaxis with no history of infection) reacted with the peptide. Epitope mapping with mouse MoAbs has shown that this peptide is located on a part of the molecule differing from immunodominant regions of the molecule identified in a previous study in Papua New Guinea.

Adolescent↗
PubMed1996

Differential effects of intra-accumbens sulpiride on cocaine-induced locomotion and conditioned place preference.

The effects of intra-accumbens sulpiride on conditioned place preference and locomotion produced by i.v. cocaine were investigated. Every other day during conditioning, rats received infusions of sulpiride (0-0.4 microgram) into the nucleus accumbens (NAc) or caudate-putamen. Fifteen min later, they were placed into a distinct compartment and injected with saline or cocaine (4.2 mg/kg, i.v.). On the alternate days, rats received sham intracranial injections and were placed into a different compartment. Locomotion and stereotypies were assessed after the first and last injection, and conditioned place preference was assessed 24 hr after the last conditioning day. After behavioral testing, receptors occupied by sulpiride were quantified by injecting rats intracranially with their respective dose of sulpiride, followed by a systemic injection of the irreversible antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). Receptors protected from EEDQ induced inactivation by sulpiride were revealed on autoradiograms of sections labeled with 3H-sulpiride. Sulpiride did not alter cocaine-conditioned place preference or cocaine-induced stereotypies. However, the two lowest doses of intra-accumbens sulpiride attenuated cocaine-induced locomotion and occupied > 42% of the sulpiride binding sites in the NAc, and the highest dose completely reversed cocaine-induced locomotion and occupied > 96% of the sulpiride binding sites in the NAc. Intracaudate sulpiride also attenuated cocaine-induced locomotion without occupying a significant number of binding sites in the NAc. These findings suggest that D2-like receptors in the NAc and anterior medial caudate-putamen are involved in cocaine-induced locomotion, but not cocaine-conditioned place preference.

Animals↗
PubMed1995

Evidence for cell-specific differences in transformation by N-, H- and K-ras.

Although Ras plays a fundamental role in cellular proliferation, differentiation and transformation, clear functional differences between the three major Ras proteins (N-, H- and K-Ras) have not as yet been demonstrated. In this study, chimeric constructs were used to compare directly transformation by N-, H- and K-ras oncogenes. In Rat-2 and NIH3T3 fibroblasts, transformation assays (anchorage independence, focus-formation and growth in 1% FCS) showed that H12-Ras was more transforming than N12-Ras or K12-Ras. By contrast, in the human multipotent haemopoietic cell line, TF-1, N12-Ras exhibited greater biological activity. Northern blotting and protein analyses indicated that these findings were not the result of differences in expression or stability of p21Ras. Using further H-ras/N-ras chimeric constructs, we found that the greater transforming activity of H12-Ras in fibroblasts was not due to the hypervariable-CAAX region, but rather to unique sequences between amino acids 84 and 143. These data demonstrate cell specific differences in the intrinsic transforming potential of N-ras, H-ras and K-ras oncogenes.

Animals↗